WALTHAM, Mass., July 17, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from clinical trials with its vascular disrupting agent (VDA) product candidate, fosbretabulin (referred to as combretastatin A4-phosphate / CA4P), will be presented at the upcoming 7th International Conference on Head and Neck Cancer in San Francisco, CA, July 19-23, 2008.
